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AbstrACt
Introduction The current American College of 
Rheumatology and European League Against 
Rheumatism treatment recommendations advise 
tapering biological disease-modifying antirheumatic 
drug (bDMARD) therapy in patients with rheumatoid 
arthritis (RA) who achieve stable clinical remission while 
receiving bDMARDs. However, not all patients maintain 
remission or low disease activity after tapering or 
discontinuation of bDMARDs. The aim of the ImPact of 
Residual Inflammation Detected via Imaging TEchniques, 
Drug Levels and Patient Characteristics on the Outcome 
of Dose TaperIng of Adalimumab in Clinical Remission 
Rheumatoid ArThritis (RA) study, or PREDICTRA, is to 
generate data on patient and disease characteristics 
that may predict the clinical course of a fixed dose-
tapering regimen with the bDMARD adalimumab.
Methods and analysis PREDICTRA is an ongoing, 
multicentre, phase IV, randomised, double-blind, 
parallel-group study of adalimumab dose tapering 
controlled by withdrawal in participants with RA who 
achieved stable clinical remission while receiving 
adalimumab. The study includes a screening period, 
a 4-week lead-in period with open-label adalimumab 
40 mg every other week and a subsequent 36-week 
double-blind period during which participants are 
randomised 5:1 to adalimumab 40 mg every 3 weeks 
(taper arm) or placebo (withdrawal arm). The primary 
explanatory efficacy variables are lead-in baseline hand 
and wrist MRI-detected synovitis and bone marrow 
oedema scores, as well as a composite of both scores; 
the dependent variable is the occurrence of flare 
up to week 40. Additional efficacy variables, safety, 
pharmacokinetics, biomarkers and immunogenicity will 
also be assessed, and an ultrasound substudy will be 
conducted.
Ethics and dissemination The study is conducted 
in accordance with the International Conference on 
Harmonisation guidelines, local laws and the ethical 
principles of the Declaration of Helsinki. All participants 
are required to sign a written informed consent 
statement before the start of any study procedures.
trial registration number EudraCT 2014-001114-26 and 
NCT02198651; Pre-results.
strengths and limitations of this study
 ► The PREDICTRA study uses both MRI and ultrasound 
imaging techniques to allow a more comprehensive 
evaluation of musculoskeletal inflammation.
 ► The randomised, double-blind, placebo-controlled 
study design reduces bias by eliminating 
expectations of treatment benefit or its loss based 
on treatment assignment.
 ► Another strength of the study is that the open-label 
rescue arm provides an opportunity to assess the 
effectiveness of retreatment with the standard 
adalimumab regimen.
 ► However, the duration of the trial may be insufficient 
to assess long-term progression of MRI-detected 
structural joint damage.
 ► Other limitations include multiple testing bias 
when investigating several possible predictors and 
the reality that some measurements are costly or 
somewhat difficult to routinely do in an outpatient 
clinic.
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IntroduCtIon  
Rheumatoid arthritis (RA) affects approximately 1% 
of the population and imposes a significant economic 
burden, resulting from both direct and indirect costs.1–3 
The primary goal of treating patients with RA under the 
treat-to-target recommendations is to maximise long-term 
health-related quality of life by controlling symptoms, 
preventing structural damage and normalising physical 
function and social participation.4 The most important 
way to achieve these goals is by abrogation of inflamma-
tion, with the treatment targets of clinical remission or low 
disease activity (LDA).4 Tumour necrosis factor inhibitor 
(TNFi) therapies effectively treat early and established 
RA, improving the disease course and halting structural 
progression.5  6 Adalimumab is a fully human immuno-
globulin G1 antibody TNFi that was initially approved for 
the treatment of adult RA.7 It has since been approved for 
13 additional indications.7  8 
For patients with RA who achieve stable clinical remis-
sion with biological disease-modifying antirheumatic 
drug (bDMARD) therapy, the current American College 
of Rheumatology (ACR) and European League Against 
Rheumatism (EULAR) treatment recommendations 
advise cautiously tapering the bDMARD (ie, reducing the 
dose or increasing the interval spacing).9  10 However, not 
all patients maintain remission or LDA after tapering or 
discontinuation of biological therapy. Controlled with-
drawal studies in patients with early RA have shown varying 
results for different TNFi agents. In the OPTIMA study in 
methotrexate-naive patients with early RA, 81% of patients 
who achieved stable LDA (Disease Activity Score based on 
28 joints (DAS28) <3.2) at weeks 22 and 26 with adalim-
umab plus methotrexate maintained disease control for 
52 weeks after discontinuing adalimumab.11 In contrast, 
in the PRIZE study in patients with early RA, only 69% of 
patients who withdrew etanercept but continued metho-
trexate therapy maintained DAS28 ≤3.2 after 39 weeks.12 
In patients with established RA, withdrawing a TNFi or 
other bDMARD has been associated with RA flares in a 
higher proportion of patients than in those with early 
RA.13 Furthermore, some patients with RA failed to main-
tain LDA or clinical remission status when assessed at 48 
weeks,14 52 weeks15 or up to 18 months16 following TNFi 
dose tapering.
Reliable parameters that would predict which patients 
can maintain adequate disease control after tapering or 
discontinuation of therapy could help guide treatment 
decisions. A number of studies over recent years have 
shown that ultrasound (US)-detected joint inflammation, 
in particular power Doppler–determined synovitis and 
to a lesser extent grayscale synovial hypertrophy (SH), 
are better predictors of relapse after bDMARD tapering 
or withdrawal than clinical measures.17–19 However, the 
added value of US to clinical examination at a patient 
level may still need to be confirmed.20 While MRI 
predictor data after bDMARD tapering or withdrawal 
are lacking, MRI-detected synovitis and bone marrow 
oedema have been demonstrated to predict radiographic 
progression in patients with RA,21  22 and MRI provides a 
reliable and responsive tool for multicentre studies (with 
central reading). In general, patients with early RA or 
those with deeper or longer clinical remission are less 
likely to experience disease flare after bDMARD tapering 
but further studies are needed to confirm these results.10 
Thus, unanswered questions related to bDMARD dose 
tapering include: (1) what patient or disease character-
istics are predictive of flare risk and (2) whether those 
characteristics could be used to devise a patient selec-
tion algorithm. Further, it is not well understood to what 
extent reinstitution of standard TNFi dosing after flare 
provides the same level of disease control as before the 
tapering.23 24 Although reinstitution of TNFi therapy 
has been successful for regaining disease control in the 
majority of patients (up to 100% of patients in some 
studies),18 23 25 not all studies have shown results that are as 
beneficial (regain of remission in only 57% of patients)26 
and patient numbers were generally low. The imPact of 
Residual inflammation detected via imaging tEchniques, 
Drug levels and patient characteristics on the outcome of 
dose taperIng of adalimumab in Clinical remission rheu-
matoid arThritis (RA) study (PREDICTRA) was designed 
to address these questions, with a particular focus on the 
predictive value of MRI-detected inflammation.
MEthods
Participants
Adult male or female participants ≥18 years of age with 
a diagnosis of RA (defined by the 1987 revised ACR clas-
sification criteria and/or the ACR/EULAR 2010 classi-
fication criteria) are eligible for study inclusion if they 
meet the following additional criteria: have been treated 
with adalimumab 40 mg every other week (eow) subcu-
taneously for ≥12 months before week 0 of the lead-in 
period and are in stable clinical remission defined 
by ≥1 documented Disease Activity Score based on 28 
joints, erythrocyte sedimentation rate (DAS28(ESR))27 
or DAS28 C reactive protein (CRP) of <2.6 (using four 
variables or three variables if patient global assessment 
(PGA) is unavailable) for ≥6 months before screening 
and DAS28(ESR) of <2.6 at screening (based on four 
variables).28 29 Concomitant methotrexate or other 
allowed conventional synthetic DMARDs (csDMARDs; 
eg, chloroquine, hydroxychloroquine, sulfasalazine, gold 
formulations and/or leflunomide) are permitted if the 
regimen has been stable for ≥12 weeks before week 0 of 
the lead-in period; the protocol allows for up to 20% of 
participants be included in the study if receiving stable 
doses of csDMARDs other than methotrexate or receiving 
adalimumab monotherapy, for at least 12 weeks before 
the week 0 lead-in visit. In addition, any concomitant oral 
corticosteroids (prednisone or equivalent) must have 
been administered at a dose of <10 mg/day that had been 
stable for ≥4 weeks before week 0 of the lead-in period 
and any nonsteroidal anti-inflammatory drugs must have 
been taken at a stable dose for ≥4 weeks before week 0 
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of the lead-in period. Exclusion criteria include any 
DAS28(ESR) or DAS28(CRP) of ≥2.6 that was assessed ≤6 
months before screening, current use of bDMARDs other 
than adalimumab and any medical condition precluding 
contrast-enhanced MRI.
study design and treatments
PREDICTRA is an ongoing, phase IV, multicentre, 
randomised, double-blind, parallel-group study of 
adalimumab dose tapering controlled with adalimumab 
withdrawal in patients with RA who achieved stable clin-
ical remission while receiving adalimumab in the clin-
ical setting (current protocol version from 25 February 
2016; registered per the WHO Trial Registration Data Set 
at h ttp: //www. clinicaltri alsr egis ter. eu (EudraCT 2014-
001114-26) and  clinicaltrials. gov (NCT02198651)). 
Study centres are located in Australia, Austria, Canada, 
France, Germany, Greece, Hungary, Ireland, Italy, the 
Netherlands, Spain, Sweden, UK and USA. The study 
includes a screening period of up to 28 days, a 4-week 
lead-in period with open-label adalimumab 40 mg 
administered subcutaneously eow and a subsequent 
36-week double-blind period during which participants 
are randomised 5:1 to adalimumab 40 mg every 3 weeks 
(taper arm) or placebo (withdrawal arm; figure 1). 
Injections of study treatment are observed during clinic 
visits to ensure proper injection technique; participants 
record each administration in the clinic and elsewhere 
for compliance documentation. During the lead-in 
period, participants undergo a contrast-enhanced MRI 
scan of the most affected hand and wrist (or dominant 
hand and wrist if both sides are equally affected) before 
the double-blind baseline visit at week 4. At the double-
blind baseline visit, only participants with DAS28(ESR) 
of <2.6 and an MRI scan quality-checked by a central 
reading centre are randomised; further study visits occur 
every 6 weeks until week 40. A flare during the double-
blind period is defined as either DAS28(ESR) >2.6 and 
an increase of >0.6 in DAS28(ESR) from double-blind 
baseline or an increase of ≥1.2 from double-blind base-
line DAS28(ESR) irrespective of absolute DAS28(ESR) 
score at any visit. If a flare occurs, that visit is denoted as 
the flare week 0 visit and the participant enters an open-
label rescue arm with standard adalimumab dosing 
(40 mg eow) and is followed for 16 weeks (subsequent 
study visits on flare weeks 4, 10 and 16).
If a participant prematurely discontinues study drug 
use, a termination visit must be completed within 2 weeks 
of the last dose of study drug and preferably prior to the 
initiation of another therapy. After discontinuation, the 
participant will be treated in accordance with the inves-
tigator's best clinical judgement. A follow-up phone call 
will be made to all participants approximately 70 days 
Figure 1 Study design. *Flare at any time point; flare defined as either (1) DAS28(ESR) ≥2.6 with an increase in DAS28(ESR) 
by >0.6 or (2) an increase in DAS28(ESR) by ≥1.2 from dbBL irrespective of absolute DAS28(ESR) score. Participants who flare at 
any time during the randomised double-blind period will be switched to open-label ADA 40 mg eow and continue in the open-
label rescue arm for 16 weeks up to a maximum study duration of 56 weeks. †If applicable. ADA, adalimumab; DAS28(CRP), 
Disease Activity Score based on 28 joints and C reactive protein; DAS28(ESR), Disease Activity Score based on 28 joints and 
erythrocyte sedimentation rate; dbBL, double-blind baseline; ew, every week; eow, every other week; e3w; every 3 weeks; F, 
flare; MTX, methotrexate; R, randomisation; RA, rheumatoid arthritis; sc, subcutaneously; US, ultrasound.  
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after the last dose of study drug to determine the status 
of any ongoing adverse events (AEs) or the occurrence 
of any new AEs. Information regarding incentives for 
participants and provisions for treating and/or compen-
sating participants who are harmed as a consequence of 
participation in the study are listed in online supplemen-
tary patient  consent form file.
blinding and treatment allocation
All study sponsor personnel with direct oversight of the 
conduct and management of the trial (with the excep-
tion of the sponsor Drug Supply Management Team), 
the investigator, study site personnel and the participants 
remain blinded to treatment throughout the double-
blind period of the study. Participants are assigned a 
unique identification number by an interactive response 
technology (IRT) system at screening and are centrally 
randomised. The treatment group assignments are not 
provided to the site. The IRT system provides access to 
participant treatment information in the case of medical 
emergency.
objectives
The overall aim of the PREDICTRA study is to generate 
data on participant and disease characteristics, including 
inflammatory markers detected by sensitive imaging tech-
niques, other biomarkers and adalimumab drug levels 
that potentially predict the clinical course (ie, the occur-
rence of flares) of the adalimumab 40 mg every 3 week 
dose-tapering regimen. The primary objective is to inves-
tigate the association between residual inflammatory 
disease activity at lead-in baseline (as detected by MRI 
scores for synovitis and osteitis) and the occurrence of 
flares in participants with RA randomised to receive a 
dose-tapering regimen of adalimumab controlled by with-
drawal of adalimumab.
Key secondary objectives include assessing the (1) 
occurrence and severity of flares and the time to flares in 
the taper and withdrawal arms; (2) association between 
double-blind baseline participant demographic and 
disease characteristics and the occurrence of flares; (3) 
association between double-blind baseline adalimumab 
trough concentrations and the occurrence of flares; (4) 
effectiveness of rescue therapy with open-label adalim-
umab 40 mg eow over 16 weeks in participants experi-
encing a flare; (5) inflammatory and structural changes 
from lead-in baseline to final visit in the taper, with-
drawal and rescue arms (based on Rheumatoid Arthritis 
MRI Score (RAMRIS)); (6) associations between lead-in 
baseline MRI and flare in subgroups of participants who 
meet additional clinical remission criteria at double-blind 
baseline, including Simplified Disease Activity Index 
(SDAI) ≤3.3, Clinical Disease Activity Index (CDAI) ≤2.8 
and ACR/EULAR 2011 Boolean-based remission; (7) 
course of disease and patient-reported outcome (PRO) 
measures in the taper, withdrawal and rescue arms 
overall and in the double-blind baseline subgroup 
and (8) incidence of participants with positive tests for 
anti-adalimumab antibodies (AAAs) in the taper and 
withdrawal arms throughout the study.
An US substudy will have the following exploratory 
objectives: to investigate the (1) association between 
double-blind baseline US scores and the occurrence of 
RA flares, (2) association between double-blind baseline 
US scores and lead-in baseline RAMRIS scores, (3) change 
in the US scores from double-blind baseline to the time of 
RA flare in the taper and withdrawal arms. A 46-joint (40 
joint areas) validated assessment and 18-tendon/tendon 
compartment assessment will be performed using gray-
scale US (GSUS) and power Doppler US (PDUS). If the 
ultrasonographer has not participated in US evaluation 
in a multicentre study in RA, training in standardisation 
of the scanning method and synovitis scoring system will 
be provided.
As a separate exploratory objective, the association 
between different biomarkers and the occurrence of 
flares will be studied in participants who provide a sepa-
rate dedicated consent. Optionally, participants may 
provide material for pharmacogenetic and RNA analyses.
Assessments and variables
Key assessments that will be performed during the study 
are listed in table 1. Overall, eight clinical domains of 
flare assessment are being evaluated: pain, function, 
swollen joints, tender joints, PGA, stiffness, fatigue and 
flare severity. Objective assessments include MRI, US, 
ESR, CRP, chemistry/haematology, rheumatoid factor, 
anticitrullinated peptide antibody, antinuclear antibodies 
and pharmacokinetics and immunogenicity (trough 
adalimumab concentrations and AAAs).
The primary explanatory efficacy variables include the 
lead-in baseline hand and wrist synovitis and osteitis (bone 
marrow oedema) RAMRIS scores as well as a composite of 
both scores; the dependent variable is the occurrence of 
flare up to week 40. Secondary efficacy variables include 
the following: time to flare; flare severity; proportion of 
participants with a flare; participant demographics and 
clinical disease characteristics at double-blind baseline; 
proportion of flared participants who regain clinical 
remission (defined as DAS28(ESR) <2.6 or DAS28(ESR) 
decrease of >1.2 if DAS28(ESR) was <2.6 at flare), propor-
tion of participants with LDA (DAS28(ESR) <3.2) and 
time to regain remission in the rescue arm; change from 
double-blind baseline in DAS28(ESR), CDAI, SDAI and 
the Health Assessment Questionnaire Disability Index 
(HAQ-DI); proportion of participants maintaining clin-
ical remission (defined as DAS28(ESR) <2.6, SDAI ≤3.3 
or CDAI ≤2.8) throughout the study; change from 
lead-in baseline to week 40 or final visit in synovitis, bone 
marrow oedema and erosions RAMRIS scores; change 
from double-blind baseline in HAQ-DI scores over time; 
proportion of participants with HAQ-DI scores ≤0.5 
at double-blind baseline and at week 40; change from 
double-blind baseline in Routine Assessment of Patient 
Index Data (RAPID 3) scores during visits; change from 
flare week 0 in RAPID 3 at-home assessments and change 
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Table 1 Key assessments in the PREDICTRA study
Assessment Timing* Scoring/Details Other
Swollen joint count 66† Screening visit and all study 
visits (and all flare week visits, if 
applicable)
Joint swelling will be classified as 
present (1), absent (0), replaced (9) or NA
Swollen joint count based on 
28 joints will be used for the 
DAS28(ESR), DAS28(CRP), SDAI 
and CDAI calculations
Tender joint count 68† Screening visit and all study 
visits (and all flare week visits, if 
applicable)
Joint pain/tenderness will be classified 
as present (1), absent (0), replaced (9) 
or NA
Tender joint count based on 
28 joints will be used for the 
DAS28(ESR), DAS28(CRP), SDAI 
and CDAI calculations
PGA of current disease 
activity (VAS)
Screening visit and all study 
visits (and all flare week visits, if 
applicable)
VAS consists of a 100 mm horizontal 
scale ranging from 0 (very low) to 100 
(very high)
The PhGA assessment will be used 
for the SDAI and CDAI calculation
PGA of disease activity 
(VAS) within 24 hours
Screening visit and all study 
visits (and all flare week visits, if 
applicable)
VAS consists of a 100 mm horizontal 
scale ranging from 0 (very well) to 100 
(very poorly)
The PGA will be used for the 
DAS28(ESR), DAS28(CRP), SDAI 
and CDAI calculations
Patient assessment of 
pain (VAS) within past 
week
Screening visit and all study 
visits (and all flare week visits, if 
applicable)
VAS consists of a 100 mm horizontal 
scale ranging from 0 (no pain) to 100 
(severe pain)
Patient assessment of 
sleep disturbance (VAS) 
within past week
Screening visit and all study 
visits (and all flare week visits, if 
applicable)
VAS consists of a 100 mm horizontal 
scale ranging from 0 (sleep is no 
problem) to 100 (sleep is a major 
problem)
Duration of morning 
stiffness
Screening visit and all study 
visits (and all flare week visits, if 
applicable)
The average daily length during the past 
week in minutes (from time of awaking to 
time of maximal improvement)
Severity of morning 
stiffness in the past week
Screening visit and all study 
visits (and all flare week visits, if 
applicable)
Rated on a numeric rating scale ranging 
from 0 (not severe) to 10 (very severe)
DAS28(ESR) Screening visit and all study 
visits (and all flare week visits, if 
applicable)
Based on four variables‡: 
DAS28(ESR)=0.56× √(TJC28)+0.28× 
√(SJC28)+0.70×(ln)(ESR)+0.014×PGA
DAS28(CRP) Screening visit and all study 
visits (and all flare week visits, if 
applicable)
Based on four variables§: 
DAS28(CRP)=0.56× 
√(TJC28)+0.28× √(SJC28)+0.36×(ln)
(CRP+1)+0.014×PGA+0.96
SDAI Screening visit and all study 
visits (and all flare week visits, if 
applicable)
SDAI=TJC28+SJC28+PhGA+PGA+CRP
CDAI Screening visit and all study 
visits (and all flare week visits, if 
applicable)
CDAI=TJC28+SJC28+PhGA+PGA
HAQ-DI All study visits starting from week 0 
of lead-in period (and all flare week 
visits, if applicable)
PRO to assess physical function and 
health-related quality of life of each 
patient
FACIT-fatigue Every other visit starting from week 
4 (ie, double-blind baseline and all 
flare week visits, if applicable)
PRO to assess current fatigue
TSQM Every other visit starting from week 
4 (ie, double-blind baseline and all 
flare week visits, if applicable)
PRO to assess satisfaction with current 
RA treatment
WPAI Weeks 4, 28 and 40 (and flare 
weeks 0, 10 and 16, if applicable)
PRO to assess impact of RA on work 
productivity and non-work activity 
limitation
SF-36 Weeks 4, 28 and 40 (and all flare 
week visits, if applicable)
PRO to assess health and well-being
Physician and patient 
assessment of flare 
severity
Flare week 0 only Assessed using a numeric rating scale 
ranging from 0 (not severe) to 10 (very 
severe)
Continued
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from double-blind baseline in swollen joint count (both 
28 and 66 joints), tender joint count (both 28 and 68 
joints), PGA of disease activity, PGA of pain, Physician 
Global Assessment of disease activity, morning stiffness 
assessment, sleep disturbance assessment, Treatment 
Satisfaction Questionnaire for Medication, Work Produc-
tivity and Activity Impairment, Short Form-36 Health 
Survey Questionnaire, Functional Assessment of Chronic 
Illness Therapy—fatigue, CRP levels and ESR.
Exploratory variables include change from double-
blind baseline to the time of flare in GSUS individual 
scores for SH, tenosynovitis and erosions, PDUS individual 
scores for synovitis/vascularisation and in a composite 
score for synovitis as well as change in the following 
biomarkers: matrix metalloproteinase 3, type I collagen 
neo-epitope, type III collagen neo-epitope, MMP-degraded 
CRP, MMP-degraded citrullinated vimentin, serum 
amyloid-associated protein, interleukin-6, chemokine 
(C-X-C motif) ligand 10 (CXCL-10) and CXCL-13.
safety
The occurrence of AEs, based on clinical and laboratory 
data, will be collected at each postscreening visit and any 
time during the study as well as for up to 70 days after 
discontinuation of study treatment.
statistical methods
Approximately 200 participants will be enrolled into the 
lead-in period of the study. Accounting for a 10% discon-
tinuation rate, the study is designed for approximately 180 
participants to enter the double-blind period (150 partic-
ipants randomised in the taper arm and 30 participants 
Assessment Timing* Scoring/Details Other
RAPID-3 All study visits starting from week 
0 of the lead-in period (and all flare 
week visits, if applicable)
Based on physical function, PGA of pain 
and patient global health
US (optional at 
investigator discretion)
Week 0 or week 4 visit before 
randomisation (and at flare week 0 
visit, if applicable)
Systematic longitudinal and transverse 
multiplanar examination of 46 joints and 
18 tendon/tendon compartments; each 
joint will be scored for B-mode synovial 
hypertrophy and synovial power Doppler 
signal on a scale of 0 to 3 (0=absent/no 
signal; 1=mild; 2=moderate; 3=marked) 
and tenosynovitis will be defined and 
scored according to the OMERACT
MRI Week 0 of the lead-in period and 
the final/early termination visit (if 
last MRI≥12 weeks before and flare 
week 16, if applicable)
MRI of the most affected hand (second 
to fifth MCP) and wrist or of the dominant 
hand and wrist (if both sides are 
considered equally affected)
Biomarkers Weeks 4, 10, 16, 28 and 40 
(and flare weeks 0, 4 and 16, if 
applicable)
Blood samples for the following 
biomarkers: MMP-3, C1M, C3M, CRPM, 
VICM, SAA, IL-6, CXCL-10, CXCL-13
Adalimumab concentration Weeks 4, 10, 16, 28 and 40 (and 
flare weeks 0, 4, 10 and 16, if 
applicable)
Blood sample for adalimumab 
concentration
Anti-adalimumab 
antibodies
Weeks 4, 10, 16, 28 and 40 (and 
flare weeks 0, 4, 10 and 16, if 
applicable)
Blood sample for anti-adalimumab 
antibody levels
*Study visits comprise the following: screening visit, week 0 (lead-in period baseline), week 4 (double-blind baseline) and weeks 10, 16, 22, 
28, 34 and 40 and early termination, if applicable. In case of a flare, study visits will subsequently consists of flare weeks 0 (ie, visit at which 
the flare is documented), 4, 10 and 16.
†The swollen and tender joint counts should be performed by a clinical assessor who will be blinded to the participants’ MRI and US results.
‡Three-variable DAS28(ESR) can be used during the trial to evaluate flare (if the PGA score is not available) using the following formula: 
DAS28(ESR) = [0.56 × √(TJC28) +0.28 × √(SJC28) +0.70 × ln(ESR)]×1.08 + 0.16.
§Three-variable DAS28(CRP) can be used during the trial to evaluate flare (if the PGA score is not available) using the following formula: 
DAS28(CRP) = [0.56 × √(TJC28) +0.28 × √(SJC28) +0.36 × ln(CRP +1)]×1.10 + 1.15.
C1M, type I collagen neo-epitope; C3M, type III collagen neo-epitope; CDAI, Clinical Disease Activity Index; CRP, C reactive protein; CRPM, 
matrix metalloproteinase-degraded CRP; CXCL-10, chemokine (C-X-C motif) ligand 10; CXCL-13, chemokine (C-X-C motif) ligand 13; DAS28, 
Disease Activity Score based on 28 joints; ESR, erythrocyte sedimentation rate; FACIT, Functional Assessment of Chronic Illness Therapy; 
HAQ-DI, Health Assessment Questionnaire–Disability Index; IL-6, interleukin-6; ln, natural logarithm; MCP, metacarpophalangeal joint; MMP-
3, matrix metalloproteinase 3; NA, no assessment; OMERACT, Outcome Measures in Rheumatology Clinical Trials; PGA, patient global 
assessment of disease activity; PhGA, physician global assessment of disease activity; PRO, patient-reported outcome; RA, rheumatoid 
arthritis; RAPID-3, Routine Assessment of Patient Index Data-3; SAA, serum amyloid-associated protein; SDAI, Simplified Disease Activity 
Index; SF-36, Short Form-36 Health Survey Questionnaire; SJC28, swollen joint count based on 28 evaluated joints; TJC28, tender joint count 
based on 28 evaluated joints; TSQM, Treatment Satisfaction Questionnaire for Medication; US, ultrasound; VAS, visual analogue scale; VICM, 
matrix metalloproteinase-degraded citrullinated vimentin; WPAI, Work Productivity and Activity Impairment.
ESR expressed as mm/hour and CRP expressed as mg/L.
Table 1 Continued 
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in the withdrawal arm) to address the primary objective. 
A sample size of 150 patients in the dose tapering group 
will ensure a precision for the estimation with the width 
of 90% CI no more than 0.03 for an OR 1.03, no more 
than 0.07 for an OR 1.1 and no more than 0.14 for an OR 
1.2 for occurrence of flare with baseline MRI score. Such 
sample size will also ensure a precision for the estimation 
of a correlation coefficient ρ with the width of 90% CI of ρ 
no more than 0.26 for a mild correlation coefficient 0.28, 
no more than 0.18 for a moderate correlation coefficient 
0.55 and no more than 0.13 for a higher correlation with 
ρ=0.67. Assuming a 30% flare rate, this sample size will 
provide the precision that the 2-sided 90% CI of the flare 
rate has a half width no more than 6%.
The analysis population for the assessment of efficacy 
and safety will include all participants who receive ≥1 dose 
of double-blind study treatment. All statistical inference 
will be based on a 2-sided alpha level of 0.1. No multi-
plicity adjustment will be conducted. The quality of the 
data will be ensured through manual and automated 
checks. The analysis will be performed using SAS (SAS 
Institute, Cary, North Carolina, USA).
For the primary objective, the main analysis will examine 
the association between the occurrence of flares and base-
line RAMRIS scores in the taper arm using logistic regres-
sion. Each OR will be calculated with a 90% CI. For this 
analysis, missing flare status for participants who discon-
tinued prematurely (ie, discontinued without detection 
of a flare) during the double-blind period will be imputed 
from the last DAS28(ESR) measurement; however, any 
participant who received rescue therapy will be consid-
ered to be flared. In addition, descriptive statistics of 
baseline RAMRIS scores will be provided for participants 
with and without a disease flare, and the between-group 
difference in the mean scores will be calculated with 90% 
CIs. Linear regression will be used to model the relation-
ship between the DAS28(ESR) at flaring (or at the end 
of study for participants without a flare) and baseline 
RAMRIS scores. Receiver operating characteristic curves 
will be used to investigate the potential flare prediction 
criteria (ie, cut-off values) based on RAMRIS scores. All 
model-based analyses may be adjusted for double-blind 
baseline values of demographic and clinical participant 
characteristics (eg, age, disease duration, previous and 
concomitant treatment) when appropriate. Similar anal-
yses will be conducted for RAMRIS synovitis scores, bone 
marrow oedema scores and the composite of both scores.
For the secondary objectives, the association between 
the specified double-blind baseline parameters and 
the occurrence of flares will be examined using similar 
analyses to those used for the assessment of the primary 
objective. In addition, the proportion of participants with 
a flare, the proportion within each level of flare severity 
and the proportion of flared participants who regain clin-
ical remission will be calculated with 90% CIs. Time to 
flare will be summarised using Kaplan-Meier survival tech-
niques. Change from baseline in the MRI scores and the 
specified clinical and health outcome measures will be 
summarised over time separately for flared and non-flared 
participants. The calculations will be performed in both 
the taper arm and the withdrawal arm.
For exploratory objectives, US scores (SH, tenosynovitis 
and erosions using GSUS; synovitis/vascularisation using 
PDUS; synovitis composite score) at double-blind base-
line, at flare and for the change between the two times 
will be summarised for participants with and without 
flares. A similar analysis will be conducted for double-
blind baseline biomarker values. In addition, a linear 
regression approach will be used to model the relation 
between the US scores and RAMRIS scores at double-
blind baseline. Additional analyses will be performed if 
deemed necessary.
The number and proportion of participants experi-
encing treatment-emergent AEs (ie, events on or after the 
first dose of study medication through the post-treatment 
assessment period) will be summarised by treatment, 
system organ class and Medical Dictionary for Regulatory 
Activities preferred term. In addition, summary of treat-
ment-emergent AEs by severity and relationship to study 
drug, as judged by the investigators, will be reported.
An interim analysis of baseline characteristics of the 
trial population is projected to occur in November 2017.
Ethics and dissemination
The study is conducted in accordance with the Interna-
tional Conference on Harmonisation guidelines, local 
laws and the ethical principles of the Declaration of 
Helsinki. All participants are required to sign a written 
informed consent statement before the start of any study 
procedures. The study sponsor abides by the Princi-
ples on Conduct of Clinical Trials and Communication 
of Clinical Trial results of the Pharmaceutical Research 
and Manufacturers of America and all relevant state 
and federal laws. Because this is a phase IV study of a 
well-established medicinal product, there is no Data 
Monitoring Committee. Each investigator maintains a 
confidential identification code list, not to be retrieved 
by AbbVie, of the participants that he or she has enrolled 
in the study. The AbbVie Quality Assurance team audits 
at least 10% of the study sites; the actual number of audits 
may be higher should the team deem it necessary to 
perform additional audits. A protocol amendment was 
submitted for approval to research ethics committees, 
institutional review boards and other applicable regula-
tory institutions. The registration at  clinicaltrials. gov was 
updated per the amendment; investigators were noti-
fied globally by newsletter and email and via individual 
follow-up to obtain a signature acknowledging receipt of 
the amendment. The final results will be shared with all 
relevant parties and disseminated through peer-reviewed 
journals and/or scientific conferences.
dIsCussIon
The PREDICTRA trial aims to assess the most compre-
hensive array of predictors, including imaging of patient 
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outcome (flare) on dose tapering of a bDMARD. The 
study was not designed to assess a treatment effect, but 
rather to predict which patients may undergo dose 
tapering of adalimumab with maintenance of RA disease 
remission.
The strengths of the PREDICTRA study include the 
use of MRI as a sensitive imaging technique, in addi-
tion to US, compared with previous trials. US does not 
detect bone marrow oedema, which, along with synovitis, 
predicts structural progression.30 Although ultrasonog-
raphy is a highly feasible tool for diagnosis and moni-
toring of patients with RA in the clinic, MRI is reliable 
and highly responsive when used (eg, to detect subclin-
ical inflammation (synovitis and osteitis)31,32) in multisite 
clinical studies. Therefore, the combined use of MRI and 
US in PREDICTRA allows for a more comprehensive eval-
uation of musculoskeletal inflammation.
The randomised, double-blind, placebo-controlled study 
design reduces bias by eliminating expectations of treatment 
benefit or its loss based on treatment assignment. The pres-
ence of a control withdrawal arm comprising one-sixth of the 
participants is also expected to encourage all participants, 
because of uncertainty about whether they are receiving 
adalimumab or not, to sensitively monitor their own symp-
toms through the PRO of PGA (a component of DAS28), 
which contributes to the definition of flare. The open-label 
rescue arm of up to 16 weeks of adalimumab therapy at 
40 mg eow provides an opportunity to assess the effective-
ness of retreatment with the standard adalimumab regimen. 
The use of MRI will also enable sensitive measurement of 
structural progression in the adalimumab taper, withdrawal 
and rescue arms relative to disease control. A limitation of 
the study design of PREDICTRA is that the duration of the 
trial may be insufficient to assess long-term progression of 
MRI-detected structural joint damage. Another limitation 
is multiple testing bias when investigating several possible 
predictors. Furthermore, some measurements are costly or 
somewhat difficult to routinely do in an outpatient clinic. 
Finally, because a validated consensus definition of RA flare 
has not yet been established,33 the ability to compare the 
results from PREDICTRA with findings from similar studies 
may be limited.
Study enrolment began in December 2014 and was 
closed in July 2017. Final results will be available in 2019.
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